Radiopharm Theranostics Limited American Depositary Shares Working Capital to Net Assets Ratio
Radiopharm Theranostics Limited American Depositary Shares working capital to net assets ratio. Radiopharm Theranostics Limited American Depositary Shares (RADX) has a Working Capital to Net Assets ratio of 13.6% as of June 2026. Working capital of $3.03 Million (current assets of $21.93 Million minus current liabilities of $18.90 Million) is measured against net assets of $22.32 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Radiopharm Theranostics Limited American tangible book value ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Radiopharm Theranostics Limited American Depositary Shares (2022–2026)
Working capital to net assets ratio of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2026. This chart shows how Radiopharm Theranostics Limited American Depositary Shares's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2022 to 2026. As of June 2026, the ratio stands at 13.6%, reflecting working capital of $3.03 Million against net assets of $22.32 Million USD. See operational self-sufficiency of Radiopharm Theranostics Limited American to measure how many days the company can operate on defensive assets alone.
Radiopharm Theranostics Limited American Depositary Shares Working Capital to Net Assets Ratio by Year (2022–2026)
Radiopharm Theranostics Limited American Depositary Shares working capital to net assets ratio by year from 2022 to 2026. The table below presents the year-by-year Working Capital to Net Assets ratio for Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2026, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Radiopharm Theranostics Limited American balance sheet assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2026 | 13.6% | $3.03 Million | $22.32 Million | $21.93 Million | $18.90 Million | ▼ -44.6 pp |
| 2025 | 58.1% | $24.92 Million | $42.87 Million | $39.85 Million | $14.93 Million | ▲ +38.9 pp |
| 2024 | 19.3% | $5.27 Million | $27.35 Million | $22.85 Million | $17.58 Million | ▲ +12.5 pp |
| 2023 | 6.7% | $3.07 Million | $45.58 Million | $16.30 Million | $13.23 Million | ▼ -24.1 pp |
| 2022 | 30.8% | $19.39 Million | $62.96 Million | $27.26 Million | $7.88 Million | — |